Skip to content

Canadian Trial of Dietary Carbohydrates in Diabetes

Long-Term Effect of Altering the Source or Amount of Dietary Carbohydrate in Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00223574
Enrollment
168
Registered
2005-09-22
Start date
2002-01-31
Completion date
2004-10-31
Last updated
2005-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

A long-term low carbohydrate, high monounsaturated fat diet, compared to a high carbohydrate, low glycemic index diet, results in more rapid progression of diabetes; i.e. increased fasting glucose and glycated hemoglobin, reduced beta-cell function and insulin sensitivity and increased free fatty acids. The deleterious effects of a high carbohydrate diet on plasma lipids are only temporary and do not persist beyond 6 months. A long-term high carbohydrate, low glycemic index diet, compared to a high carbohydrate, high glycemic index diet, improves glycemic control and beta-cell function

Interventions

DRUGControl - high carbohydrate, high glycemic index foods
DRUGhigh carbohydrate, low glycemic index foods
DRUGlow carbohydrate, high monounsaturate fat foods

Sponsors

University of Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* male or non-pregnant/non-lactating females with type 2 diabetes treated by diet alone * age 53-75y * body mass index 25-40kg/m\^2 (Caucasian) or 23-40kg/m\^2 (other) * HbA1c \<=130% of upper limit of normal of local hospital lab

Exclusion criteria

* use of any hypoglycemic or anti-hyperglycemic drug within 6 months of randomization * major cardiovascular event or major surgery within 6 months of randomization * serum triglycerides \>10mmol/L * presence of other major debilitating disorder such as liver disease, renal failure or cancer * presence of gastrointestinal disorder or use of drug which is likely to alter gastrointestinal motility or nutrient absorption * use of oral steroids * substance or alcohol abuse * simultaneous participation in another clinical trial * allergy or intolerance to more than one of wheat, barley, corn, oats, potato, legumes, nuts, psyllium, olives, avocado or canola * unwilling or unable to follow the protocol and/or give informed consent * subjects planning to be on holiday for more than 8 weeks in a row or a total of 12 weeks in the year in locations to which they will not take study food

Design outcomes

Primary

MeasureTime frame
glycated hemoglobin

Secondary

MeasureTime frame
waist circumference
occurrence of diet failure
fasting glucose
fasting C-reactive protein
fasting lipids (total, HDL and LDL cholesterol and triglcyerides)
fasting apolipoproteins A1 and B100
fasting free fatty acids
Body weight
plasma glucose and insulin 30, 60 and 120min after 75g oral glucose
insulin sensitivity (HOMA)
beta-cell function (30min-fasting insulin)/(30min-fasting glucose)
metabolic profile (glucose, insulin, triglycerides and FFA during 8h profile)
quality of life
gastrointestinal symptoms
diet satisfactio
fasting short chain fatty acids

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026